EuPFI 2021 - Taste Assessment Study of Belumosudil to Inform an Integrated Paediatric Formulation Development Program
Presentied at the annual EuPFI event, this poster dicuments the project of Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders.
Candidate Selection Webinar
Join Us for our Candidate Selection Webinar on November 17, 2021. This webinar explains the benefits of adopting a holistic approach at the candidate selection-development interface. The tight integration of the drug substance, biopharmaceutics and drug product activities, encourages cross-functional workflows enabling chemists to talk to formulators and DMPK scientists to talk to clinicians, for example.
ISSX NA 2021 - An Integrated Radiolabelled Study to Determine the Mass Balance, Metabolite Profile and Identification and absolute bioavailability of Nolasiban in Healthy Female Subjects
Presented at the 24th North American ISSX Meeting, in this poster, we determine Mass Balance, Metabolite Profile and Identification and Absolute Bioavailability of Nolasiban in Healthy Female Subjects, via an integrated radiolabelled study.
Integrated Programs: Early Development
Simplify early development and accelerate to Proof-of Concept Proof-of-Concept (POC) is a key milestone in the development of a new drug candidate. At Quotient Sciences, we understand the increasing pressures on R&D budgets, therefore the need to transition molecules through early development to POC needs to be fast and cost-effective.
Accelerating Peptide Development: Strategies to optimize the formulation and manufacture of peptide therapeutics
This webinar reviews the challenges when developing a peptide formulation, investigates the best route of delivery for your molecule, alongside looking into formulation strategies and manufacturing considerations, before exploring options for an integrated approach to accelerate peptide development.
Quotient Sciences Corporate Brochure 2021
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Our corporate brochure provides a key summary of who we are, what we represent, our services and our marketplace differentiation.
Designated team of highly experienced personnel who control all aspects of sample management and liaise closely with clients throughout the lifecycle of stability studies. Our aim is to provide robust, sound data on which shelf life and expiration dates for drug substance and drug products can be based. Whatever the phase of development our team can offer support. We also offer a stability protocol creation service if clients prefer not to supply stability protocols themselves. Robust systems are in place to ensure complete tracking of samples from receipt, through stability storage and time-point testing (or shipment if required), to study end.
Quotient Sciences' extensive experience permits testing of difficult products that have not previously been analyzed. We are specialists at the microbial analysis of radiolabelled compounds and are able to handle cytotoxic, high potency compounds and controlled substances. Our flexible approach allows us to offer both on-site microbiological testing and analysis of products made off-site.
Whether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.
Determining drug exposure is vital for the assessment of drug safety and efficacy. Quotient's Bioanalytical team, develop and refine methods so exposure can be assessed reliably and accurately in a variety of biological matrices.
Drug Substance Synthesis and Manufacturing
Tactical deployment of best-in-class synthesis technologies to minimize chemistry costs and move your drug substance supply off the critical path.